Skybiotech Healthcare
BSE: SKYBIOTECH · Other Textile Products
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Skybiotech Healthcare's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Skybiotech Healthcare Limited is an Indian company engaged in the trading and distribution of pharmaceutical products, including generic medicines, over-the-counter drugs, and healthcare supplements. It operates as a small-cap entity focused on supplying quality formulations to a network of domestic distributors and retailers.
Business Model
The company generates revenue by sourcing pharmaceutical products and distributing them through an established supply chain network across India. Its model relies on capitalising on the demand for affordable healthcare solutions within the competitive domestic market.
Management Commentary
Management is focused on expanding the company's product portfolio and strengthening its supply chain infrastructure to enhance market presence. The firm aims to leverage the growing demand for affordable healthcare to improve its competitive standing.
Growth Outlook
Growth is expected to be driven by the expansion of the product portfolio and the strengthening of the existing supply chain network. The company aims to capture a larger share of the domestic market by addressing the rising demand for affordable healthcare.
Key Risks
- Regulatory Compliance. The pharmaceutical distribution sector is subject to stringent government regulations and quality control standards that may impact operations.
- Market Competition. The company faces intense competition from both established pharmaceutical players and numerous small-scale distributors in the Indian market.
- Supply Chain Disruptions. Reliance on third-party sourcing makes the company vulnerable to supply chain interruptions and fluctuations in procurement costs.
- Pricing Pressure. Government-mandated price controls on essential medicines may limit profit margins for generic and over-the-counter products.
Start your research today
Unlock AI insights, financials, peers and live data on Skybiotech Healthcare and 5,000+ companies — free.
Key Metrics
REVENUE
₹7 Cr
TTM · consolidated
NET PROFIT
₹1 Cr
TTM · consolidated
EPS
₹5.79
TTM · consolidated
RETURN ON EQUITY
12.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
9.5%
TTM · consolidated
P/E
23.6x
Q4 FY26 · consolidated
EV/EBITDA
17.1x
Q4 FY26 · consolidated
EBITDA MARGIN
30.3%
TTM · consolidated
NET PROFIT MARGIN
16.4%
Q4 FY26 · consolidated
DEBT TO EQUITY
1.1x
Q4 FY26 · consolidated
Peers · Other Textile Products
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Skybiotech HealthcareSKYBIOTECH | ₹25 Cr | 22.42 | 15.20 | -5.7% | 30.3% | 12.7% | 9.5% | — |
Raghuvir Synthetics Ltd.RAGHUSYN | ₹367 Cr | 25.24 | 17.63 | -23.3% | 9.7% | 41.8% | 25.5% | -23.0% |
Axita CottonAXITA | ₹308 Cr | 80.50 | 37.62 | -58.4% | 3.0% | 6.1% | 11.7% | -8.5% |
Vardhman PolytexVARDMNPOLY | ₹289 Cr | 0.91 | 13.84 | -15.2% | 10.4% | -150.1% | 279.9% | -33.4% |
R&B DenimsRNBDENIMS | ₹265 Cr | 4.87 | 6.45 | — | 10.8% | 10.5% | 12.5% | -89.7% |
Le Merite ExportLEMERITE | ₹262 Cr | — | — | — | 4.0% | — | — | -94.2% |
As of Q4 FY26
Financials
Skybiotech Healthcare
BSE: SKYBIOTECH · Other Textile Products
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Skybiotech Healthcare's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Skybiotech Healthcare Limited is an Indian company engaged in the trading and distribution of pharmaceutical products, including generic medicines, over-the-counter drugs, and healthcare supplements. It operates as a small-cap entity focused on supplying quality formulations to a network of domestic distributors and retailers.
Business Model
The company generates revenue by sourcing pharmaceutical products and distributing them through an established supply chain network across India. Its model relies on capitalising on the demand for affordable healthcare solutions within the competitive domestic market.
Management Commentary
Management is focused on expanding the company's product portfolio and strengthening its supply chain infrastructure to enhance market presence. The firm aims to leverage the growing demand for affordable healthcare to improve its competitive standing.
Growth Outlook
Growth is expected to be driven by the expansion of the product portfolio and the strengthening of the existing supply chain network. The company aims to capture a larger share of the domestic market by addressing the rising demand for affordable healthcare.
Key Risks
- Regulatory Compliance. The pharmaceutical distribution sector is subject to stringent government regulations and quality control standards that may impact operations.
- Market Competition. The company faces intense competition from both established pharmaceutical players and numerous small-scale distributors in the Indian market.
- Supply Chain Disruptions. Reliance on third-party sourcing makes the company vulnerable to supply chain interruptions and fluctuations in procurement costs.
- Pricing Pressure. Government-mandated price controls on essential medicines may limit profit margins for generic and over-the-counter products.
Start your research today
Unlock AI insights, financials, peers and live data on Skybiotech Healthcare and 5,000+ companies — free.
Key Metrics
REVENUE
₹7 Cr
TTM · consolidated
NET PROFIT
₹1 Cr
TTM · consolidated
EPS
₹5.79
TTM · consolidated
RETURN ON EQUITY
12.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
9.5%
TTM · consolidated
P/E
23.6x
Q4 FY26 · consolidated
EV/EBITDA
17.1x
Q4 FY26 · consolidated
EBITDA MARGIN
30.3%
TTM · consolidated
NET PROFIT MARGIN
16.4%
Q4 FY26 · consolidated
DEBT TO EQUITY
1.1x
Q4 FY26 · consolidated
Peers · Other Textile Products
As of Q4 FY26